Copyright Seeking Alpha
Hims & Hers gains as analysts welcome talks with Novo for Wegovy sales Comments Hims & Hers Health (HIMS) traded ~6% higher on Tuesday after the telehealth platform, with its Q3 2025 results, said it is in "active discussions" with Novo Nordisk (NVO) to sell the Danish drugmaker’s weight-loss therapy Wegovy. The California-based health Quick Insights The disclosure of active discussions led to a positive share price reaction, with analysts optimistic it could boost business if a deal is reached. Q3 earnings missed expectations even though online and compounded Wegovy sales drove a revenue beat, raising concerns, but future guidance aligns with consensus. International expansion and personalized treatment plans are seen to offset increased risk and support longer-term investment appeal. Recommended For You More Trending News
